Protocols›Hormonal & longevity›Aesthetics & Physique
← Protocols
Community · convergenceAthlete / performance · uptakeNo approved clinical use

Aesthetics & Physique

Stack: GHK-Cu + Ipamorelin + AOD-9604 + Collagen Peptides · skin / physique polish
"A skin-and-polish stack. GHK-Cu has fair topical skin data; the physique claims attached to the rest are weak. Looks good on a label, thin underneath."
GoalSkin / physique polish
Compounds4 · GHK-Cu + Ipamorelin + AOD-9604 + Collagen Peptides
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not licensed medicines here · FDA (US): not approved · skin data fair, physique claims weak
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Community
Where / who
Community / athlete and clinic use as tagged above.
Use status
Popular aesthetics-focused pattern.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
Ipamorelin / AOD-9604: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Skin data fair; physique claims weak.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

GHK-Cu has the strongest case here (topical skin data); collagen is a mild supplement signal. AOD-9604 and the GH-axis additions carry the physique claims, which are weakly evidenced.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Moderate

Popular aesthetics-focused pattern.

Human efficacy Weak

Skin data fair; physique claims weak.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

One fair component, several weak ones.

Fast facts
Compounds

GHK-Cu · Ipamorelin · AOD-9604 · Collagen Peptides

Humans exposed (est.)

Moderate — undocumented.

UK strip

GREEN — research material